Mergers & Acquisitions Scorecard

 

Regardless of industry, the ebb and flow of mergers and acquisitions (M&A) reveal much about companies and their response to competitive, economic and political forces. Currently, the pharmaceutical manufacturing industry is working through an extraordinary period, responding to both dramatic change and incredible opportunity with a surge of M&A activity that has its players seeking to bolster core strengths, market share, strategic competitive agility or all of the above. No matter where you hang your hat in the Pharma industry, it's important to keep up with who's buying whom, who's joining forces, and who's being sold off, especially for those managing production assets because a merger or an acquisition can have such a dramatic and often negative impact on operational excellence and ultimately product quality.

To that end, we offer our own M&A Scorecard, a resource for staying up-to-date on the major players in the industry.

Abbott Labs

July 15, 2014

• Abbott Laboratories will sell its generic drug business in established markets to Mylan Inc. who will form a new company that will be incorporated
in the Netherlands.

Read more

June 24, 2014

• Abbott announced an agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer, for between $395 million to $495 million.

read more

May 16, 2014

• Abbott Laboratories announced that it agreed to buy Chile-based CFR Pharmaceuticals for $2.9 billion to expand business in growing Latin American markets.

Read more
Back to Top

AbbVie

July 21, 2014

• AbbVie Inc. acquired Shire Plc for $54.7 billion. According to a Reuters article, the deal will cut AbbVie's U.S. tax bill and its reliance on arthritis drug Humira, the world's top selling medicine which loses U.S. patent protection in 2016.

Read More
Back to Top

Actavis

July 2, 2014

• Actavis' subsidiary Forest Laboratories has completed its acquisition of Furiex Pharmaceuticals Inc. in a cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

Read More

April 2, 2014

• Actavis plc, a global specialty pharmaceutical company, announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for about $100 million in cash.

Read more

February 18, 2014

• Actavis plc and Forest Laboratories Inc. announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share.

Read more
Back to Top

Akorn

May 9, 2014

• Akorn Inc. has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million in cash.

Read More
Back to Top

Astrazeneca

May 19, 2014

• The board of AstraZeneca rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer

REad more
Back to Top

Bayer

May 15, 2014

• Bayer HealthCare will sell its Interventional device business to Boston Scientific for $415 million.

Read more

May 6, 2014

• Bayer will acquire the consumer care business of Merck & Co. Inc., Whitehouse Station, NJ, for a purchase price of $14.2 billion

Read More
Back to Top

Baxter

April 2, 2014

• Baxter International Inc. has agreed to acquire privately held Chatham Therapeutics for an initial payment of $70 million, giving Baxter access to developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

Read more

July 30, 2014

• Baxter International will sell its portfolio of marketed vaccines to Pfizer for $635 million.

Read More
Back to Top

Boehringer Ingelheim

May 28, 2014

• Boehringer Ingelheim's Bedford Laboratories will sell its U.S. injectable generics business operated by Ohio-based subsidiary Ben Venue Laboratories to London-based Hikma Pharmaceuticals for a total consideration of up to $300 million. In addition, Hikma will potentially acquire all of the assets of the troubled Ben Venue manufacturing site in Bedford, Ohio.

Read more
Back to Top

Eli Lilly

April 22, 2014

• Eli Lilly will buy Novartis' Animal Health business for roughly $5.4B.

Read more
Back to Top

Forest Laboratories

Feb 18, 2014

• Actavis plc and Forest Laboratories Inc. announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share.

read more

Jan 8, 2014

• Forest Laboratories will acquire Aptalis, a privately-held leading specialty pharmaceutical company, from TPG, the global private investment firm, for $2.9 billion in cash, pending required reviews by anti-trust authorities.

read more
Back to Top

Glaxosmithkline

April 22, 2014

• GSK will sell its Oncology business to Novartis for $14.5 billion upfront, plus up to $1.5 billion more if certain milestones are met.
• Novartis and GSK will create a new Consumer Health Care business through a joint venture that will combine Novartis’ over-the-counter drug business with GSK’s consumer business. Novartis will own 36.5% of the new "GSK Consumer Healthcare" venture, leaving GSK with 63.5% and managerial control.

Click Here
Back to Top

Horizon Pharma

March 19, 2014

• Horizon Pharma, an Illinois-based specialty pharma company, acquired Dublin-based Vidara Therapeutics in a $600 million cash-and-stock reverse merger that will enable Horizon to capitalize on Ireland's low corporate tax rates.

Read more
Back to Top

J&J

Jan 16, 2014

• Johnson & Johnson said it would sell its ortho clinical diagnostics division to the Carlyle Group LP for $4.15 billion, shedding a slow-growing business to focus on more lucrative products.

read more

Jan 16, 2014

• Johnson & Johnson will sell its Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, to the Carlyle Group global alternative asset manager for $4.15 billion.

read more
Back to Top

Merck

June 9, 2014

• Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area.

Read more

May 13, 2014

• Merck agreed to sell the Asian rights to its ophthalmics business to Japan’s Santen Pharmaceutical for $600 million.

Read more

May 1, 2014

• Merck & Co. sells its microbial process development and manufacturing operations in Boulder, Colorado to North Carolina-based KBI Biopharma. Specific terms of the deal were not disclosed, however Merck bought the Boulder plant in 2009 for $130 million.

Read more
Back to Top

Mylan

July 15, 2014

• Mylan Inc. is buying Abbott Laboratories’ generic drug business in established markets and forming a new company that will be incorporated in the Netherlands

Read more
Back to Top

Novartis

April 22, 2014

• Novartis will buy GSK’s Oncology business for $14.5 billion upfront, plus up to $1.5 billion more if certain milestones are met.
• Novartis will sell its Vaccine business, excluding the flu portion, to GSK for $7.1B, plus royalties.
• Novartis will sell its Animal Health business to Eli Lilly for roughly $5.4B.
• Novartis and GSK will create a new Consumer Health Care business through a joint venture that will combine Novartis’ over-the-counter drug business with GSK’s consumer business. Novartis will own 36.5% of the new "GSK Consumer Healthcare" venture, leaving GSK with 63.5% and managerial control.

Read more

February 17, 2014

• Novartis AG announced it will acquire CoStim Pharmaceuticals Inc., expanding its reach in immunotherapeutics, a new field of cancer drugs that may reach $35 billion in annual sales.

Read more
Back to Top

Pfizer

July 30, 2014

• Pfizer Inc. announced that it will acquire Baxter International’s portfolio of marketed vaccines for $635 million.

Read more

July 16, 2014

• Pfizer Inc. and InnoPharma Inc., a privately held pharmaceutical development company, have entered into an agreement under which Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

Read more
Back to Top

Roche

August 25, 2014

• Roche and InterMune Inc. have entered into a merger agreement for Roche to acquire InterMune at a price of $74 per share in an all-cash transaction, or about $8.3 billion on a fully diluted basis.

Read More

August 5, 2014

• Roche announced it will acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark, for up to $450M.

Read more

July 2, 2014

• Roche announced that Genentech will acquire Seragon Pharmaceuticals Inc., a privately held biotechnology company based in San Diego, California for an upfront cash payment of $725 million, plus additional contingent payments of up to $1 billion based on achievement of certain predetermined milestones.

Read More
Back to Top

Shire

July 21, 2014

• Shire has been acquired by AbbVie Inc. for $54.7 billion. According to a Reuters article, the deal will cut AbbVie's U.S. tax bill and its reliance on arthritis drug Humira, the world's top selling medicine which loses U.S. patent protection in 2016.

Read more

May 12, 2014

• Shire will acquire Lumena Pharmaceuticals for an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.

Read more
Back to Top

Sun Pharmaceutical

April 7, 2014

• Sun Pharmaceutical Industries Ltd. agreed to buy competitor Ranbaxy Laboratories Ltd. for $3.2 billion from Japan’s Daiichi Sankyo Co.

Read more
Back to Top

Teva

June 3, 2014

• Teva will acquire Labrys Biologics for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments, broadening Teva’s array of biotechnology assets and capabilities.

Read more

Jan 21, 2014

• Teva Pharmaceutical Industries will acquire NuPathe Inc. for $3.65 per share in cash, or $144 million, to expand its portfolio of medicines to treat conditions affecting the central nervous system.

read more
Back to Top

Valeant

July 10, 2014

•Valeant Pharmaceuticals announced today the completed sale to Swiss food giant Nestle of commercialization rights to several key injectable aesthetic dermatology products in the U.S. and Canada for $1.4B cash.

Read more
Back to Top